Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
12.17
0.00 (0.00%)
At close: Sep 4, 2026, 4:00 PM EDT
12.12
-0.05 (-0.44%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 310.00K CHF in the quarter ending June 30, 2026, with 18.77% growth. This brings the company's revenue in the last twelve months to 1.17M, up 53.33% year-over-year. In the year 2025, Oculis Holding AG had annual revenue of 1.20M with 74.78% growth.
Revenue (ttm)
1.17M CHF
Revenue Growth
+53.33%
P/S Ratio
517.51
Revenue / Employee
19,550 CHF
Employees
60
Market Cap
751.28M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 239.66M |
| Zevra Therapeutics | 136.07M |
| Gyre Therapeutics | 109.82M |
| Verastem | 87.53M |
| Assembly Biosciences | 74.85M |
| Neurogene | 925.00K |
OCS News
- 14 days ago - First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis - GlobeNewsWire
- 24 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 4 weeks ago - Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company - GlobeNewsWire
- 4 weeks ago - Oculis Reports Q2 2026 Financial Results and Provides Company Update - GlobeNewsWire
- 4 weeks ago - Oculis Holding AG Earnings release: Q2 2026 - Filings
- 5 weeks ago - Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - GlobeNewsWire
- 2 months ago - Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - GlobeNewsWire
- 2 months ago - Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - GlobeNewsWire